DGAP-News

Press Release: 4SC publishes results for financial year 2014

DGAP-News: 4SC AG / Key word(s): Final Results/Miscellaneous
Press Release: 4SC publishes results for financial year 2014

25.03.2015 / 07:30

---------------------------------------------------------------------

Press Release

4SC publishes results for financial year 2014

Planegg-Martinsried, Germany, 25 March 2015 - 4SC AG (Frankfurt, Prime
Standard: VSC), a discovery and development company of targeted small
molecule drugs for cancer and autoimmune diseases, today published the
financial results of the 4SC Group for the financial year ended 31 December
2014.

Key figures for the 2014 financial year:

- Revenue up 44% and consolidated operating result up 11%.

- Earnings per share improve by 10% to EUR -0.19.

- Cash reach extends to beyond the first quarter of 2016.

Key operating events during the 2014 financial year:

- Resminostat: 4SC's licensing partner Yakult Honsha successfully
completes a clinical Phase I trial in Japanese patients with solid
tumours and makes a milestone payment to 4SC (May 2014). Yakult also
successfully completes two further clinical Phase I study parts in
liver cancer (HCC) and non-small-cell lung cancer (NSCLC), and starts
the Phase II study parts of the Phase I/II trials in both indications
(Sep./Oct. 2014).

- Resminostat: 4SC, in-house, is far advanced in the preparation of a
planned Phase II liver cancer trial in Western patient populations and
has also evaluated further development options for resminostat in
additional indications.

- 4SC-202: Positive Phase I data with promising indications of
anti-tumour activity in patients with advanced haematological tumours
presented at the ASCO Annual Meeting in Chicago (June 2014). Overall,
83% of patients benefited from the treatment. One patient, who
exhibited a complete remission of the tumour lesions upon treatment
with 4SC-202, was treated in the study for a period of 28 months. 4SC
has started negotiations for the further clinical development (Phase
II) with potential partners and investors.

- 4SC-205: Positive results reported from Phase I AEGIS study (Dec.
2014).

- Strengthening of short- and medium-term financing: Convertible note
agreement of up to EUR 15 million signed with US Investor Yorkville
(Feb. 2014) plus conclusion of loan agreement of up to EUR 10 million
with main shareholder Santo Holding (June 2014).

Key operating events after the reporting date: